Table 1 Patient baseline data sheet from TCGA-BRCA
From: Upregulation of CENPM promotes breast carcinogenesis by altering immune infiltration
Characteristic | Low expression of CENPM | High expression of CENPM | p |
|---|---|---|---|
n | 541 | 542 | |
T stage, n (%) | < 0.001 | ||
T1 | 173 (16%) | 104 (9.6%) | |
T2 | 290 (26.9%) | 339 (31.4%) | |
T3 | 59 (5.5%) | 80 (7.4%) | |
T4 | 19 (1.8%) | 16 (1.5%) | |
N stage, n (%) | 0.782 | ||
N0 | 256 (24.1%) | 258 (24.2%) | |
N1 | 181 (17%) | 177 (16.6%) | |
N2 | 54 (5.1%) | 62 (5.8%) | |
N3 | 41 (3.9%) | 35 (3.3%) | |
M stage, n (%) | 1.000 | ||
M0 | 450 (48.8%) | 452 (49%) | |
M1 | 10 (1.1%) | 10 (1.1%) | |
Pathologic stage, n (%) | 0.015 | ||
Stage I | 109 (10.3%) | 72 (6.8%) | |
Stage II | 295 (27.8%) | 324 (30.6%) | |
Stage III | 112 (10.6%) | 130 (12.3%) | |
Stage IV | 10 (0.9%) | 8 (0.8%) | |
Race, n (%) | < 0.001 | ||
Asian | 22 (2.2%) | 38 (3.8%) | |
Black or African American | 51 (5.1%) | 130 (13.1%) | |
White | 434 (43.7%) | 319 (32.1%) | |
Age, n (%) | 0.286 | ||
< = 60 | 291 (26.9%) | 310 (28.6%) | |
> 60 | 250 (23.1%) | 232 (21.4%) | |
Histological type, n (%) | < 0.001 | ||
Infiltrating Ductal Carcinoma | 355 (36.3%) | 417 (42.7%) | |
Infiltrating Lobular Carcinoma | 133 (13.6%) | 72 (7.4%) | |
ER status, n (%) | < 0.001 | ||
Negative | 77 (7.4%) | 163 (15.7%) | |
Indeterminate | 0 (0%) | 2 (0.2%) | |
Positive | 439 (42.4%) | 354 (34.2%) | |
PR status, n (%) | < 0.001 | ||
Negative | 123 (11.9%) | 219 (21.2%) | |
Indeterminate | 2 (0.2%) | 2 (0.2%) | |
Positive | 390 (37.7%) | 298 (28.8%) | |
HER2 status, n (%) | 0.052 | ||
Negative | 298 (41%) | 260 (35.8%) | |
Indeterminate | 7 (1%) | 5 (0.7%) | |
Positive | 67 (9.2%) | 90 (12.4%) | |
PAM50, n (%) | < 0.001 | ||
Normal | 29 (2.7%) | 11 (1%) | |
LumA | 386 (35.6%) | 176 (16.3%) | |
LumB | 55 (5.1%) | 149 (13.8%) | |
Her2 | 29 (2.7%) | 53 (4.9%) | |
Basal | 42 (3.9%) | 153 (14.1%) | |
Menopause status, n (%) | 0.963 | ||
Pre | 118 (12.1%) | 111 (11.4%) | |
Peri | 21 (2.2%) | 19 (2%) | |
Post | 357 (36.7%) | 346 (35.6%) | |
Anatomic neoplasm subdivisions, n (%) | 1.000 | ||
Left | 281 (25.9%) | 282 (26%) | |
Right | 260 (24%) | 260 (24%) | |
Age, median (IQR) | 59 (48, 67) | 58 (49, 67) | 0.573 |